Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?

M.M. Said; M.P.G. Broen; E.L. Swart; I.H. Bartelink; M.C.M. Kouwenhoven

doi:10.3390/cancers15051561

Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?

M.M. Said, M.P.G. Broen, E.L. Swart, I.H. Bartelink, M.C.M. Kouwenhoven^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Article number	1561
Number of pages	7
Journal	Cancers
Volume	15
Issue number	5
DOIs	https://doi.org/10.3390/cancers15051561
Publication status	Published - 1 Mar 2023

Keywords

NEWLY-DIAGNOSED GLIOBLASTOMA
POPULATION PHARMACOKINETICS
MALIGNANT GLIOMA
STANDARD TREATMENT
AMERICAN SOCIETY
OPEN-LABEL
PHASE-II
MGMT
MYELOSUPPRESSION
RADIOTHERAPY

Access to Document

10.3390/cancers15051561Licence: CC BY

Cite this

@article{92795ae179434b6699a94a3aacffcc3d,

title = "Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?",

keywords = "NEWLY-DIAGNOSED GLIOBLASTOMA, POPULATION PHARMACOKINETICS, MALIGNANT GLIOMA, STANDARD TREATMENT, AMERICAN SOCIETY, OPEN-LABEL, PHASE-II, MGMT, MYELOSUPPRESSION, RADIOTHERAPY",

author = "M.M. Said and M.P.G. Broen and E.L. Swart and I.H. Bartelink and M.C.M. Kouwenhoven",

year = "2023",

month = mar,

day = "1",

doi = "10.3390/cancers15051561",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",